2026 NPPES data Speech-Language Pathologist NPI 1861816282 PA-C
Verify on CMS →

BETHANY ARMENDARIZ, PA-C

Speech-Language Pathologist in EL PASO, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
2K
Medicare Part D claims · 372 beneficiaries · Speech-Language Pathologist avg: 323
Generic prescribing
91%
generic claims · 9% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
95.75/100
▲ 13 pts above national avg 83.1 · [object Object]
Industry payments
$1.1K
35 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

BETHANY ARMENDARIZ, PA-C reported a CMS MIPS final score of 95.75/100 — above the 83.1 national average — and filed 1,758 Medicare Part D claims in 2023.

95.75/100
MIPS score · +13 vs avg
2K
Part D claims, 2023
91%
generic prescribing
$1.1K
industry payments (Sunshine Act)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

BETHANY ARMENDARIZ, PA-C's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

96 Top 21% higher than 79% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

What does the federal data show about BETHANY ARMENDARIZ, PA-C?

High performer (top quartile)

NPI registry status

Active

Issued 02/05/2014

NPI 1861816282

Primary specialty

Speech-Language Pathologist

High-volume

188,278 US NPIs in this specialty

Medicare Part D claims

1,758 444% vs specialty avg

2023 prescription claims

Specialty avg: 323

MIPS final score

95.75/100 12.650000000000006% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Texas

How Speech-Language Pathologist compares to other specialties among Texas providers

Texas providers

Speech-Language Pathologist share within Texas

1. Speech-Language Pathologist42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Speech-Language Pathologist share within Texas

Medicare quality performance — MIPS

BETHANY ARMENDARIZ, PA-C's 2023 MIPS final score plotted against the Speech-Language Pathologist national average

High performer (top quartile)
MIPS Final Score
95.75/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Speech-Language Pathologist) — 95.75/100 vs national avg 83.1

0%100%National avg83%95.8%
MIPS final score (Speech-Language Pathologist) — 95.75/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

BETHANY ARMENDARIZ, PA-C appears in the CMS NPPES registry as a Speech-Language Pathologist provider holding PA-C credentials at 1509 CIDRA DEL SOL, EL PASO, TX, 79911, with a listed phone of (214) 223-2779. NPI 1861816282 was issued on 02/05/2014. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ARMENDARIZ most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,758 prescription claims written by this provider, covering 372 Medicare beneficiaries and totaling roughly $890K in drug spend, split 9% brand-name and 91% generic by claim count, with an opioid prescribing rate of 6.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 95.75/100 for the 2023 performance year, compared with the national average of 83.1.

Speech-Language Pathologist is a high-volume specialty nationwide, with 188,278 enrolled providers across 55 states and an average of 323 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1509 CIDRA DEL SOL
EL PASO, TX 79911

Provider Details

NPI 1861816282
Specialty Speech-Language Pathologist
Credentials PA-C
Gender Female
NPI Issued 02/05/2014

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

95.75
Final Score
Avg: 83.1
95
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where BETHANY ARMENDARIZ, PA-C bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

RIO GRANDE UROLOGY PA
EL PASO, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for BETHANY ARMENDARIZ, PA-C. Source: openpaymentsdata.cms.gov.

Total received

$1.1K

Largest payer

Bayer Healthcare Pharmaceuticals Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to BETHANY ARMENDARIZ, PA-C. To verify BETHANY ARMENDARIZ, PA-C's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Generic-heavy

BETHANY ARMENDARIZ, PA-C — brand share 9.0%
Specialty average (est.)

9% brand-name claims vs 91% generic, on 1,758 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,758
Total Claims
$890K
Total Drug Cost
372
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
2,597
Total Day Supply
64,176
Brand vs Generic
9% brand / 91% generic
Brand Drug Cost
$340K
Generic Drug Cost
$549K
Opioid Claims
107 (6.1% rate)
Antibiotic Claims
113

Patient Demographics

Average Patient Age
73.5 years
Avg HCC Risk Score
1.62
Gender Split
0% female / 100% male
Age Distribution
<65: 13, 65-74: 202, 75-84: 138, 85+: 19

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What BETHANY ARMENDARIZ, PA-C prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Tamsulosin Hcl
321
Prednisone
254
Abiraterone Acetate
252
Ciprofloxacin Hcl
104
Acetaminophen-Codeine
Acetaminophen With Codeine
100
Dexamethasone
99
Alendronate Sodium
95
Lorazepam
89
Myrbetriq
Mirabegron
82
Orgovyx
Relugolix
71

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Speech-Language Pathologist Overview

How BETHANY ARMENDARIZ, PA-C fits within the Speech-Language Pathologist landscape nationally.

188,278
Speech-Language Pathologist Providers in US
55
States with Speech-Language Pathologist
323
Avg Claims per Provider

BETHANY ARMENDARIZ, PA-C's 1,758 claims are above the specialty average of 323.

Nearby Speech-Language Pathologist Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as ARMENDARIZ.

Compare Speech-Language Pathologist nationally: see state-by-state distribution →

Frequently Asked Questions

What is BETHANY ARMENDARIZ, PA-C's specialty?
BETHANY ARMENDARIZ, PA-C specializes in Speech-Language Pathologist and practices in EL PASO, Texas. Credentials: PA-C.
How much does BETHANY ARMENDARIZ, PA-C prescribe under Medicare Part D?
In 2023, BETHANY ARMENDARIZ, PA-C wrote 1,758 Medicare Part D claims totaling $890K in drug costs for 372 beneficiaries.
What is BETHANY ARMENDARIZ, PA-C's Medicare quality score?
BETHANY ARMENDARIZ, PA-C has a CMS MIPS Final Score of 95.75/100. The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is BETHANY ARMENDARIZ, PA-C located?
BETHANY ARMENDARIZ, PA-C is located at 1509 CIDRA DEL SOL, EL PASO, TX, 79911. Phone: (214) 223-2779.
What is BETHANY ARMENDARIZ, PA-C's NPI number?
BETHANY ARMENDARIZ, PA-C's National Provider Identifier (NPI) is 1861816282, issued on 02/05/2014.
Does BETHANY ARMENDARIZ, PA-C prescribe more brand-name or generic drugs?
BETHANY ARMENDARIZ, PA-C's prescribing is 9% brand-name and 91% generic drugs by claim count, with $340K in brand drug costs.
Does BETHANY ARMENDARIZ, PA-C prescribe opioids?
Yes, BETHANY ARMENDARIZ, PA-C had 107 opioid claims in 2023 with an opioid prescribing rate of 6.1%.
How many Speech-Language Pathologist providers are there in the US?
There are 188,278 Speech-Language Pathologist providers across 55 states in the US. The average Speech-Language Pathologist provider writes 323 Medicare Part D claims per year.
What drugs does BETHANY ARMENDARIZ, PA-C prescribe most often?
Based on 2023 Medicare Part D data, BETHANY ARMENDARIZ, PA-C's most frequently prescribed drugs include Tamsulosin Hcl, Prednisone, Abiraterone Acetate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does BETHANY ARMENDARIZ, PA-C accept Medicare?
BETHANY ARMENDARIZ, PA-C appears in CMS Medicare data with 1,758 Part D claims and 372 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify BETHANY ARMENDARIZ, PA-C's credentials?
BETHANY ARMENDARIZ, PA-C's NPI is 1861816282 with credentials PA-C. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology